Physician profile
Diep H Bui
NPI 1649400359
$2,928.23
in general payments reported to CMS, 2019-2025
25 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $886 · 2020: $73.30 · 2021: $186 · 2022: $119 · 2023: $706 · 2024: $592 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.23 |
| Education | $373.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $565.17 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $448.47 | 2019-2025 | Fintepla, Nayzilam, Briviact |
| Sk Life Science, INC. | $265.97 | 2020-2024 | Xcopri |
| Neurocrine Biosciences, INC. | $228.22 | 2022-2023 | Ingrezza, Ongentys |
| Amgen INC. | $181.16 | 2019 | |
| Neurelis, INC. | $162.20 | 2023-2025 | Valtoco |
| Astrazeneca Pharmaceuticals Lp | $139.28 | 2021 | |
| Allergan, INC. | $131.92 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $131.10 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $105.04 | 2023-2025 | |
| Lilly USA, LLC | $76.56 | 2019 | |
| Greenwich Biosciences, INC. | $73.59 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $68.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.98 | 2019 | |
| Averitas Pharma INC. | $40.08 | 2024 | Qutenza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otter Pharmaceuticals, LLC | $37.31 | 2025 | Sympazan |
| Livanova USA, INC. | $32.63 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $32.48 | 2023 | Daybue |
| Aucta Pharmaceuticals, INC. | $28.78 | 2024-2025 | Motpoly Xr |
| Alnylam Pharmaceuticals INC. | $24.33 | 2023 | Onpattro |
| Emd Serono, INC. | $24.08 | 2020 | |
| Genzyme Corporation | $22.03 | 2021 | |
| Biogen, INC. | $21.05 | 2019 | |
| Csl Behring | $20.00 | 2025 | Hizentra |
| Aquestive Therapeutics, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diep Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.